AUTL
Autolus Therapeutics plc
$1.70
+0.09 (+5.59%)
At close · Jul 8
Market Cap
$452.46M
Shares
266,155,786
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.70
Open$1.60
Day$1.60–1.75
52W$1.18–2.70
Avg vol 30d1.2M
Short int13.5M · 5.1% float · 10.2d
Short vol32%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
+6%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
34%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+24%
trailing
YTD return
−15%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
3 of 84 funds reported for Jun 30 · net +19.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.06% of float · ▲ +5.4% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
84 holders — mid 3-yr range
Squeeze score
86
high risk · 0–100
Fundamentals
Revenue growth
+496%
Y/Y
EPS growth
−26%
Y/Y
Free cash flow
$-302.6M
Balance sheet
$104.1M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 16, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
AUCATZYL net product revenue
· full year 2026
Maintained
$120M – $135M
prior FY $75.39M
midpoint +69.1% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
34%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
3 of 84 funds reported for Jun 30 · net +19.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.06% of float · ▲ +5.4% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
84 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 34%
52-wk high $3
vs 200-day avg +10%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| U.S. centers | 73 | Q1 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AUTL
this stock
Autolus Therapeutics plc
|
$452.46M | -14.6% | +496.0% | — | 5.1% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AUTL | +6.3% | +16.4% | +24.1% | +6.3% | -14.6% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +6.4% | +15.6% | +16.7% | +6.4% | -23.9% |